Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.

Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce their strategic partnership, aimed at revolutionizing the biopharma industry. By leveraging Partex’s proprietary AI (Artificial Intelligence) technology and Anavex’s innovative precision medicine drug development platform, we seek to enhance patient outcomes and reshape the future of healthcare.

Dr. Gunjan Bhardwaj, CEO of Partex NV, expressed his excitement, stating, “Together with Anavex, we embark on this impactful journey to extend our patient ecosystem. Our Life Sciences Language Processing platform with Generative Artificial Intelligence capabilities will significantly improve patient outcomes.”

Dr. Christopher Missling, PhD, President and CEO of Anavex Life Sciences, added, “We are thrilled to collaborate with Partex and fully embrace AI to expand beyond R&D into healthcare sales marketing. Our expertise in precision medicine drug development, combined with Partex’s disruptive approach, will bring better treatment options to patients in a truly patient-centric manner.”

Stay tuned for the groundbreaking advancements we’ll achieve together. Together, we are reshaping the future of biopharma.

on May 30, 2024

Cookie	Duration	Description
cookie-checkbox-analytics	11 months	The cookie is used to store the user consent for the cookies in the category "Analytics".
cookie-checkbox-functional	11 months	The cookie is set to record the user consent for the cookies in the category "Functional".
cookie-checkbox-necessary	11 months	The cookies are used to store the user consent for the cookies in the category "Necessary".
cookie-checkbox-others	11 months	This cookie is used to store the user consent for the cookies in the category "Other.
cookie-checkbox-performance	11 months	The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is used to store whether or not a user has consented to the use of cookies. It does not store any personal data.

Latest Posts

What’s New in Ontosight^® Terminal 1.1

30

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

22

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Featured News

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven

Partex NV announces collaboration with Althea DRF Lifesciences to provide

Innovative AI technology in oncology: Partex Group presents results from

Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment

Innoplexus and AIO Studien gGmbH are jointly announcing the start